Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.62 |
| ▸ | LCK | P06239 | 1/20 | 0.56 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.51 |
| ▸ | F7 | P08709 | 1/20 | 0.48 |
| ▸ | F3 | P13726 | 1/20 | 0.48 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.48 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.48 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.48 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.48 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.48 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.48 |
| ▸ | SIRT4 | Q9Y6E7 | 1/20 | 0.48 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.47 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.47 |
| ▸ | AURKA | O14965 | 1/20 | 0.47 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.47 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.47 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.47 |
| ▸ | PAK4 | O96013 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29522657 | 1.00 | AR (0.62) | ARLCKSMYD3CYP3A4F7 | |
| SCHEMBL6648425 | 0.93 | AR (0.55) | ARLCKSMYD3CYP3A4F7 | |
| SCHEMBL29972759 | 0.93 | AR (0.55) | ARLCKSMYD3CYP3A4F7 | |
| SCHEMBL18318801 | 0.86 | AR (0.64) | ARCYP3A4MAP4K4MKNK1MKNK2 | |
| SCHEMBL113378 | 0.83 | SMYD3 (0.55) | ARSMYD3CYP3A4HIPK2IMPDH2 | |
| SCHEMBL29489099 | 0.83 | SMYD3 (0.55) | ARSMYD3CYP3A4HIPK2IMPDH2 | |
| SCHEMBL2363489 | 0.82 | LCK (0.78) | LCKPLAUKDM4E | |
| SCHEMBL12765931 | 0.81 | SMYD3 (0.50) | ARSMYD3CYP3A4HIPK2IMPDH2 | |
| SCHEMBL3126130 | 0.81 | IMPDH2 (0.53) | ARSMYD3CYP3A4HIPK2IMPDH2 | |
| Hydrochloric Acid SCHEMBL7557776 | 0.81 | SMYD3 (0.54) | ARSMYD3CYP3A4HIPK2IMPDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3536685-B1 | BICYCLIC-FUSED HETEROARYL OR ARYL COMPOUNDS AND THEIR USE AS IRAK4 INHIBITORS | PFIZER (US) | 2022-02-16 | — | — | EP | claimed |
| WO-2019111218-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS IRAK4 INHIBITORS | CADILA HEALTHCARE LIMITED (IN) | 2019-06-13 | — | — | WO | claimed |
| CN-105163727-B | Stimulate neurogenetic isoquinilone derivatives | 豪夫迈·罗氏有限公司 | 2018-08-17 | — | — | CN | claimed |
| CN-106458912-A | Bicyclic fused heteroaryl or aryl compounds and their use as IRAK4 mimetics | 辉瑞公司 | 2017-02-22 | — | — | CN | claimed |
| CN-105163727-A | Neurogenesis-stimulating isoquinoline derivatives | HOFFMANN LA ROCHE | 2015-12-16 | — | — | CN | claimed |
| US-8410273-B2 | Cyclic compound having substituted phenyl group | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-04-02 | — | — | US | claimed |
| WO-2009150196-A1 | N-THIAZOLYL-1, 2, 3, 4-TETRAHYDRO-6-ISOQUINOLINECARBOXAMIDE DERIVATIVES AS INHIBITORS OF STEAROYL COENZYME A DESATURASE | SMITHKLINE BEECHAM CORPORATION (US) | 2009-12-17 | — | — | WO | claimed |
| EP-2125799-A1 | THIADIAZOLE DERIVATIVES, INHIBITORS OF STEAROYL-COA DESATURASE | Smithkline Beecham Corporation (US) | 2009-12-02 | — | — | EP | claimed |
| WO-2008104524-A1 | THIADIAZOLE DERIVATIVES, INHIBITORS OF STEAROYL-COA DESATURASE | SMITHKLINE BEECHAM CORPORATION (US) | 2008-09-04 | — | — | WO | claimed |
| EP-3826722-B1 | ISOQUINOLINE COMPOUNDS AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2026-02-18 | — | — | EP | disclosed |
| US-12378249-B2 | Isoquinoline compounds and uses thereof | GENENTECH, INC. (US) | 2025-08-05 | — | — | US | disclosed |
| US-12202836-B2 | Bicyclic-fused heteroaryl or aryl compounds | PFIZER INC. (US) | 2025-01-21 | — | — | US | disclosed |
| US-12103902-B2 | Bicyclic compounds | VIVACE THERAPEUTICS, INC. (US) | 2024-10-01 | — | — | US | disclosed |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| EP-1904449-A2 | INHIBITORS OF CHECKPOINT KINASES | Merck & Co., Inc. (US) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007008502-A2 | INHIBITORS OF CHECKPOINT KINASES | MERCK & CO., INC. (US) | 2007-01-18 | — | — | WO | disclosed |
| US-5747511-A | TREATMENT OF HERPES INFECTIONS | SRI INTERNATIONAL (US) | 1998-05-05 | — | — | US | disclosed |
| EP-0712404-A1 | NOVEL BENZOTHIOPHENE ANALOGS AS ANTIVIRAL AGENTS | STANFORD RES INST INT (US) | 1996-05-22 | — | — | EP | disclosed |
| US-4396619-A | ANTIBIOTICS | ELI LILLY AND COMPANY (US) | 1983-08-02 | — | — | US | disclosed |
| US-4382932-A | Isoquinolinium substituted cephalosporins | ELI LILLY AND COMPANY (US) | 1983-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12378249-B2 | Isoquinoline compounds and uses thereof | HIPK1, HPGDS, IP6K1 | AR 4768/4885LCK 213/4885SMYD3 2138/4885 |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | IRAK1, IRAK4, IRAK2 | AR 3804/4885LCK 706/4885SMYD3 3811/4885 |
| US-12103902-B2 | Bicyclic compounds | YAP1, TEAD2, TEAD3 | AR 1088/4885LCK 632/4885SMYD3 1887/4885 |
| US-12202836-B2 | Bicyclic-fused heteroaryl or aryl compounds | TTR, TYR, ABL1 | AR 175/4885LCK 19/4885SMYD3 3117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.